In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novartis licenses Xencor's cancer immunotherapy candidates, XmAb technology

Executive Summary

Xencor Inc. and Novartis Institutes for BioMedical Research Inc. will jointly collaborate on the development of bispecific antibodies as cancer immunotherapeutics, using Xencor's XmAb antibody engineering platform.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register